<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18279075</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-1899</ISSN><JournalIssue CitedMedium="Print"><Volume>197</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication.</ArticleTitle><Pagination><StartPage>854</StartPage><EndPage>857</EndPage><MedlinePgn>854-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1086/527326</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) causes fatal encephalitis in young children. However, there is no effective antiviral drug available for infected patients. Ribavirin is currently used for the treatment of several RNA virus infections clinically, so its anti-EV71 efficacy was evaluated. In vitro results showed that ribavirin effectively reduced the viral yields (with an IC50 of 65 microg/mL) and virus-induced cytopathic effect in human and mouse cell lines. In vivo results showed that ribavirin reduced the mortality, morbidity, and subsequent paralysis sequelae in infected mice by decreasing viral loads in tissues. Thus, ribavirin could be a potential anti-EV71 drug.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhao-Hong</ForeName><Initials>ZH</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University,Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chien-Ming</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Pin</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Fang-Hsiu</ForeName><Initials>FH</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shih-Heng</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ching-Chuan</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Chun-Keung</ForeName><Initials>CK</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shun-Hua</ForeName><Initials>SH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>3</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18279075</ArticleId><ArticleId IdType="pmc">PMC7109938</ArticleId><ArticleId IdType="doi">10.1086/527326</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nolan MA, Craig ME, Lahra MM, et al. Survival after pulmonary edema due to enterovirus 71 encephaliti. Neurology. 2003;60:1651&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12771257</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Grou. N Engl J Med. 1999;341:929&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Huang LM, Gau SS, et al. Neurodevelopment and cognition in children after enterovirus 71 infectio. N Engl J Med. 2007;356:1226&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">17377160</ArticleId></ArticleIdList></Reference><Reference><Citation>Shia KS, Li WT, Chang CM, et al. Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitor. J Med Chem. 2002;45:1644&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">11931618</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirsi JJ, North JA, McKernan PA, et al. Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agen. Antimicrob Agents Chemother. 1983;24:353&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC185325</ArticleId><ArticleId IdType="pubmed">6615611</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishimoto C, Crumpacker CS, Abelmann WH. Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subset. J Am Coll Cardiol. 1988;12:1334&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">2844874</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumortier J, Ducos E, Scoazec JY, Chevallier P, Boillot O, Gagnieu MC. Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantatio. J Viral Hepat. 2006;13:538&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16901284</ArticleId></ArticleIdList></Reference><Reference><Citation>Jairath S, Vargas PB, Hamlin HA, Field AK, Kilkuskie RE. Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotide. Antiviral Res. 1997;33:201&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">9037376</ArticleId></ArticleIdList></Reference><Reference><Citation>McJunkin JE, Khan R, de los Reyes EC, et al. Treatment of severe La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biops. Pediatrics. 1997;99:261&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9024460</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong HT, Kamarulzaman A, Tan CT, et al. Treatment of acute Nipah encephalitis with ribaviri. Ann Neurol. 2001;49:810&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">11409437</ArticleId></ArticleIdList></Reference><Reference><Citation>Remesar MC, Blejer JL, Weissenbacher MC, Nejamkis MR. Ribavirin effect on experimental Junin virus-induced encephaliti. J Med Virol. 1988;26:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">2846772</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters CJ, Reynolds JA, Slone TW, Jones DE, Stephen EL. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activato. Antiviral Res. 1986;6:285&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">2429616</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Chou CT, Lei HY, et al. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infectio. J Virol. 2004;78:7916&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC446098</ArticleId><ArticleId IdType="pubmed">15254164</ArticleId></ArticleIdList></Reference><Reference><Citation>Georges-Courbot MC, Contamin H, Faure C, et al. Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infectio. Antimicrob Agents Chemother. 2006;50:1768&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1472238</ArticleId><ArticleId IdType="pubmed">16641448</ArticleId></ArticleIdList></Reference><Reference><Citation>Crance JM, Scaramozzino N, Jouan A, Garin D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruse. Antiviral Res. 2003;58:73&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12719009</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor E, Morrison S, Lane J, Oleske J, Sonke RL, Connor J. Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infectio. Antimicrob Agents Chemother. 1993;37:532&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC187703</ArticleId><ArticleId IdType="pubmed">8460922</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito Y, Escuret V, Durantel D, Zoulim F, Schinazi RF, Agrofoglio LA. Synthesis of 1,2,3-triazolo-carbanucleoside analogues of ribavirin targeting an HCV in replico. Bioorg Med Chem. 2003;11:3633&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12901908</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassidy LF, Patterson JL. Mechanism of La Crosse virus inhibition by ribaviri. Antimicrob Agents Chemother. 1989;33:2009&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC172805</ArticleId><ArticleId IdType="pubmed">2610511</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosoya M, Mori S, Tomoda A, et al. Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephaliti. Antimicrob Agents Chemother. 2004;48:4631&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC529186</ArticleId><ArticleId IdType="pubmed">15561836</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy ME, Kariwa H, Mizutani T, Yoshimatsu K, Arikawa J, Takashima I. In vitro antiviral activity of lactoferrin and ribavirin upon hantaviru. Arch Virol. 2000;145:1571&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">11003470</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunther S, Asper M, Roser C, et al. Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitr. Antiviral Res. 2004;63:209&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7126008</ArticleId><ArticleId IdType="pubmed">15451189</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ML, Lee YP, Wang YF, et al. Type I interferons protect mice against enterovirus 71 infectio. J Gen Virol. 2005;86:3263&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298971</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>